4-Hydroxytamoxifen, an Active Metabolite of Tamoxifen, Does Not Alter the Radiation Sensitivity of MCF-7 Breast Carcinoma Cells Irradiated in Vitro

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1994 Jan 1

PMID 7949215

Citations 6

Authors

J N Sarkaria

E M Miller

C J Parker

V C Jordan

R T Mulcahy

Affiliations

Soon will be listed here.

Abstract

The effect of 4-hydroxytamoxifen (4OH-TAM), the potent anti-estrogenic metabolite of tamoxifen, on the radiosensitivity of MCF-7 cells irradiated in vitro was determined. Radiation dose response curves were generated for MCF-7 cells maintained and irradiated in phenol red-free medium containing 10(-10) M estradiol (E2) with or without 10(-7) M 4OH-TAM. Immediately after irradiation cells were transferred to medium containing 10(-10) ME2 supplemented with bovine serum to stimulate colony formation. Estradiol-stimulated cell proliferation was inhibited by 10(-7) M 4OH-TAM, but radiation sensitivity was not significantly altered (p > 0.3). Continued incubation in the absence of E2 for an additional 24 hours after irradiation likewise failed to alter the radiosensitivity of 4OH-TAM-treated MCF-7 cells. These studies indicate that growth-inhibitory concentrations of the anti-estrogen 4OH-TAM do not modify the in vitro radiation sensitivity of this line of human breast carcinoma cells.

Citing Articles

Estrogen Receptor Signaling in Radiotherapy: From Molecular Mechanisms to Clinical Studies.

Rong C, Meinert E, Hess J Int J Mol Sci. 2018; 19(3).

PMID: 29498642 PMC: 5877574. DOI: 10.3390/ijms19030713.

Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms.

Fang Q, Yao S, Luo G, Zhang X Oncotarget. 2018; 9(2):2475-2501.

PMID: 29416786 PMC: 5788654. DOI: 10.18632/oncotarget.23504.

Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.

Yavas G, Yavas C, Acar H, Toy H, Yuce D, Ata O Support Care Cancer. 2012; 21(3):811-7.

PMID: 22941118 DOI: 10.1007/s00520-012-1584-7.

Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation.

Shao C, Folkard M, Held K, Prise K BMC Cancer. 2008; 8:184.

PMID: 18590532 PMC: 2443807. DOI: 10.1186/1471-2407-8-184.

Letrozole sensitizes breast cancer cells to ionizing radiation.

Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P Breast Cancer Res. 2005; 7(1):R156-63.

PMID: 15642164 PMC: 1064115. DOI: 10.1186/bcr969.

References

Lykkesfeldt A, Larsen J, Christensen I, Briand P . Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. Br J Cancer. 1984; 49(6):717-22. PMC: 1976853. DOI: 10.1038/bjc.1984.113. View

Kinsella T, Gould M, Mulcahy R, Ritter M, Fowler J . Keynote address: integration of cytostatic agents and radiation therapy: a different approach to "proliferating" human tumors. Int J Radiat Oncol Biol Phys. 1991; 20(2):295-302. DOI: 10.1016/0360-3016(91)90108-g. View

. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. Br J Cancer. 1988; 57(6):608-11. PMC: 2246455. DOI: 10.1038/bjc.1988.138. View

Rutqvist L, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L . Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer. 1990; 66(1):89-96. DOI: 10.1002/1097-0142(19900701)66:1<89::aid-cncr2820660117>3.0.co;2-g. View

JENG M, Parker C, Jordan V . Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 1992; 52(23):6539-46. View

Wazer D, Tercilla O, Lin P, Schmidt-Ullrich R . Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br J Radiol. 1989; 62(744):1079-83. DOI: 10.1259/0007-1285-62-744-1079. View

Lindstrom M, Kunugi K, Kinsella T . Global comparison of radiation and chemotherapy dose-response curves with a test for interaction. Radiat Res. 1993; 135(2):269-77. View

Iliakis G . Radiation-induced potentially lethal damage: DNA lesions susceptible to fixation. Int J Radiat Biol Relat Stud Phys Chem Med. 1988; 53(4):541-84. DOI: 10.1080/09553008814550901. View

Rew D, Campbell I, Taylor I, Wilson G . Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2'-deoxyuridine labelling: a flow cytometric study of 75 tumours. Br J Surg. 1992; 79(4):335-9. DOI: 10.1002/bjs.1800790418. View

10.

Jordan V, Collins M, Rowsby L, Prestwich G . A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977; 75(2):305-16. DOI: 10.1677/joe.0.0750305. View

11.

. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992; 339(8784):1-15. View

12.

Osborne C, Boldt D, Estrada P . Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984; 44(4):1433-9. View

13.

Gould M, Clifton K . The survival of rat mammary gland cells following irradiation in vivo under different endocrinological conditions. Int J Radiat Oncol Biol Phys. 1978; 4(7-8):629-32. DOI: 10.1016/0360-3016(78)90185-2. View

14.

Mouridsen H, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S . Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol. 1988; 27(6A):699-705. DOI: 10.3109/02841868809091772. View

15.

Ryden S, Ferno M, Moller T, Aspegren K, BERGLJUNG L, KILLANDER D . Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol. 1992; 31(2):271-4. DOI: 10.3109/02841869209088914. View

16.

SOULE H, Vazguez J, Long A, Albert S, Brennan M . A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973; 51(5):1409-16. DOI: 10.1093/jnci/51.5.1409. View

17.

Brosing J, Giese W, Mulcahy R . Lack of a differential radiation response for proliferative and non-proliferative rat thyroid cells (FRTL-5) in vitro. Int J Radiat Oncol Biol Phys. 1989; 16(6):1511-7. DOI: 10.1016/0360-3016(89)90956-5. View

18.

Fisher B, Costantino J, Redmond C, POISSON R, Bowman D, Couture J . A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320(8):479-84. DOI: 10.1056/NEJM198902233200802. View

19.

. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group. Eur J Cancer. 1992; 28A(4-5):904-7. View

20.

Osborne C, Boldt D, Clark G, Trent J . Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983; 43(8):3583-5. View